A Resource for Healthcare and Social Services Professionals
Buprenorphine Extended-Release Implementation Guide
This comprehensive guide outlines key components for the successful implementation of buprenorphine extended-release injection for the treatment of opioid use disorder. It covers relevant definitions, identifies regulatory bodies, and highlights educational resources and tools to ensure regulatory compliance while providing high-quality patient care.
Download fileBuprenorphine Extended-Release Injection: An Instructional Guide
This instructional video provides a comprehensive overview of extended-release injectable buprenorphine for the treatment of opioid use disorder, focusing on the two FDA-approved forms: Sublocade® and Brixadi®. The video includes step-by-step demonstrations of how to properly prepare and administer each formulation. Viewers will learn about proper site selection, needle placement, and post-injection care. Additionally, safety protocols and potential side effects are covered.
Boston Medical Center Injectable Buprenorphine Protocols
Please reference the 2021 Boston Medical Center OBAT Clinical Guidelines, pages 42-50. These guidelines should be used to inform the administration of injectable buprenorphine at Boston Medical Center.
Visit webpageBrixadi® Dosing Conversion Tables
Suggested Brixadi® corresponding dosage for patients transitioning from daily sublingual buprenorphine or monthly Sublocade® treatment to monthly or weekly Brixadi® treatment. Tables show the suggested corresponding Brixadi® dose based on current sublingual buprenorphine or Sublocade® dosage.
Download fileExtended-Release Injectable Buprenorphine Administration Checklist
Checklist for extended-release injectable buprenorphine administration. Please reference the 2021 "Addiction Nursing Competencies: A Comprehensive Toolkit for the Addictions Nurse" document, pages 62-63.
Visit webpageFormulation Selection Tool for Extended-Release Injectable Buprenorphine
This tool outlines considerations for each FDA-approved extended-release injectable buprenorphine formulation.
Download fileInitiation of Brixadi® Extended-Release Injectable Buprenorphine for Opioid Use Disorder
Guidance for starting a patient on Brixadi® extended-release injectable buprenorphine for the treatment of opioid use disorder. This is not meant to replace clinical decision-making.
Download fileInitiation of Sublocade® Extended-Release Injectable Buprenorphine for Opioid Use Disorder
Guidance for starting a patient on Sublocade® extended-release injectable buprenorphine for the treatment of opioid use disorder. This is not meant to replace clinical decision-making.
Download file Lidocaine Administration Prior to Extended-Release Buprenorphine Injection Protocols | Boston Medical Center
Boston Medical Center's Policy and Procedure Manual's Standing Order for Administration of Lidocaine prior to injection of extended-release injectable buprenorphine.
Consent for Treatment with Brixadi®
Consent for Treatment with Sublocade®
Brixadi® Patient Education Sheet
Buprenorphine Patient Education Sheet
This informational sheet for patients covers what buprenorphine is, how it works, how it is typically administered, possible side effects, and other important things to know.
Visit webpage Sublocade® Patient Education Sheet
Grayken Center for Addiction TTA is a program of Boston Medical Center (BMC), a 514-bed academic medical center located in Boston's historic South End and the largest safety-net hospital in New England.
The content on this site and the content presented by Grayken Center for Addiction TTA is intended solely to inform and educate healthcare and social service professionals, and shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional. The hospital, the program, and the contributors are not acting as health care providers or professional consultants on behalf of any specific patient and disclaim establishing a provider-patient relationship with any specific patient.